Skip to content
Boca Raton City Online – Lifestyle
Author:
Innovent Biologics,Inc
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
October 23, 2026
/DISREGARD RELEASE: Innovent Biologics/
October 23, 2026
2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS
October 23, 2026
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
October 13, 2026
2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma
September 29, 2026
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
September 28, 2026
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
September 27, 2026
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
September 23, 2026
Innovent Announces 2026 Interim Results and Business Updates
August 25, 2026
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
August 9, 2026
1
2
3
Next Page
→